What is Taxotere
DocetaxelThe Generic name of this drug
Treatment SummaryDocetaxel is an anti-cancer drug used to treat breast, ovarian, and non-small cell lung cancer. The medication works by binding to a protein found in cells called tubulin, which stops the growth of cancer cells.
Taxotereis the brand name
Taxotere Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Taxotere
Docetaxel
2008
97
Approved as Treatment by the FDA
Docetaxel, also known as Taxotere, is approved by the FDA for 12 uses such as Squamous Cell Carcinoma of Head and Neck and Malignant Neoplasms .Squamous Cell Carcinoma of Head and Neck
Malignant Neoplasms
Used to treat Node Positive Breast Cancer in combination with Cyclophosphamide
BRCA1 gene
Metastatic Breast Cancer
Advance Directives
Neoplasm Metastasis
Advance Directives
Used to treat advanced untreated gastric adenocarcinoma in combination with Cisplatin
metastatic untreated non small cell lung cancer
Used to treat metastatic untreated non small cell lung cancer in combination with Cisplatin
Non-Small Cell Lung Carcinoma
Metastatic Hormone-Refractory Prostate Cancer
Used to treat refractory, metastatic hormone-refractory Prostate cancer in combination with Prednisone
Advance Directives
Used to treat locally advanced Squamous cell carcinoma of head and neck in combination with Cisplatin
Advance Directives
Used to treat locally advanced untreated non small cell lung cancer in combination with Cisplatin
Effectiveness
How Taxotere Affects PatientsDocetaxel is a drug used to treat cancer. It helps create and stabilize microtubules, which are necessary for many cell functions. Docetaxel also changes the way microtubules are organized, which can prevent cancer cells from dividing and growing.
How Taxotere works in the bodyDocetaxel stops cancer cells from reproducing by blocking the growth of their microtubules. This is done by locking the "building blocks" of microtubules (tubulin) in place, preventing them from moving around. This interferes with cell function, as this movement of microtubules is important for transporting chromosomes during mitosis (cell division). Additionally, docetaxel works by binding to a protein called Bcl-2, which stops cells from undergoing programmed cell death (apoptosis). By binding to this protein, docetaxel prevents it from working and allows the cell to die.
When to interrupt dosage
The advised dosage of Taxotere is contingent upon the determined condition, for example, Esophageal Cancer, Neoplasm Metastasis and Non-Small Cell Lung Carcinoma. The measure of dosage deviates, in accordance with the approach of administration (e.g. Intravenous or Injection, solution, concentrate - Intravenous) presented in the following table.Condition
Dosage
Administration
Esophageal Cancer
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Neoplasm Metastasis
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Non-Small Cell Lung Carcinoma
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Advance Directives
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Advance Directives
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Sarcoma
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
metastatic untreated non small cell lung cancer
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Advance Directives
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Metastatic Breast Cancer
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Advance Directives
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Metastatic Hormone-Refractory Prostate Cancer
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Malignant Neoplasms
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Head
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Small Cell Lung Cancer
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Soft Tissue Sarcoma
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Metastatic Bladder Cancer
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
BRCA1 gene
80.0 mg/mL, , 20.0 mg/mL, 16.0 mg/mL, 200.0 mg/mL, 20.0 mg, 40.0 mg/mL, 160.0 mg/mL, 80.0 mg, 10.0 mg/mL, 140.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL
Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, Injection - Intravenous, , Solution, Kit, Solution - Intravenous, Injection, solution - Intravenous, Kit; Solution - Intravenous, Injection, solution, Kit; Solution
Warnings
Taxotere has one contraindication and should not be used when encountering the conditions contained in the following table.Taxotere ContraindicationsCondition
Risk Level
Notes
neutrophil count <1500 cells/mm3
Do Not Combine
Common Taxotere Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Docetaxel.
Abetimus
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.
Taxotere Toxicity & Overdose RiskThe most toxic dose of this drug in rats is greater than 2000mg/kg. An overdose could lead to problems with the bone marrow, peripheral nerve damage, and irritation of the mucous membranes. Two people who overdosed on this drug experienced severe low white blood cell counts, fatigue, skin reactions, and tingling. They both recovered without any major problems.
Taxotere Novel Uses: Which Conditions Have a Clinical Trial Featuring Taxotere?
378 active trials are being conducted to assess the potential of Taxotere to combat metastatic untreated non small cell lung cancer, Sarcoma and Advance Directives.Condition
Clinical Trials
Trial Phases
Advance Directives
0 Actively Recruiting
Esophageal Cancer
75 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3
Soft Tissue Sarcoma
64 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1
metastatic untreated non small cell lung cancer
0 Actively Recruiting
Sarcoma
1 Actively Recruiting
Phase 2
Advance Directives
0 Actively Recruiting
Metastatic Breast Cancer
89 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4
Non-Small Cell Lung Carcinoma
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
BRCA1 gene
11 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3
Advance Directives
0 Actively Recruiting
Small Cell Lung Cancer
64 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Phase 4, Early Phase 1
Malignant Neoplasms
1 Actively Recruiting
Not Applicable
Metastatic Hormone-Refractory Prostate Cancer
89 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
Neoplasm Metastasis
1 Actively Recruiting
Phase 2
Head
0 Actively Recruiting
Metastatic Bladder Cancer
4 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Taxotere Reviews: What are patients saying about Taxotere?
4.7Patient Review
8/8/2016 I was diagnosed with Triple Negative Breast Cancer and started Taxotere immediately. Almost all of my hair fell out, as well as my nails. The nail beds turned black and now, 3 months later, the nails are coming off. My hair is slowly growing back but it's a different texture. I didn't have any unexpected side effects which was great.
3.7Patient Review
4/13/2015 I've only had 2 out of 6 infusions. Too early to tell if its effective. Will update after next PSA test. My tolerance is very good. The only negatives were an early swelling of hands (now OK) and fatigue; both side affects have improved since then, however.
3.3Patient Review
6/29/2011 I've only just started taking this medication, so I don't have a ton of information yet.
3.3Patient Review
3/3/20103.3Patient Review
1/31/2013 2003 is when I was treated with this drug. I had an allergic reaction in which my feet burned like I walked on hot coals. I could not walk and soon layers and layers of the skin peeled off and lost toenails and finger nails and all the skin on my hands. Ever since I have had severe nerve damage. I do not have active cancer however. They did switch me to Taxol to finish my treatments.
2.7Patient Review
8/18/2011 Taxotere caused me significant and permanent damage to my lungs. If you find yourself short of breath after this treatment, please get examined by a doctor immediately.
2.7Patient Review
3/5/20102.3Patient Review
7/20/2011 I've had three infusions of this treatment. While it has been successful in reducing my PSA levels, I have also had reactions to it during the infusion process that have caused chest and neck pain.
2Patient Review
9/11/2011 I constantly had diarrhea, felt nauseous, and experienced chronic pain in my muscles and joints.
2Patient Review
3/14/2014 i had every side effect mentioned, great for working on cancer, horable working on you it's a killer. wound up with chf,copd,more lung trouble. took myself off the drug after 9 sessions. now trying to rehab.
1Patient Review
7/22/2010 I've been taking Taxotere for seven months now, and the constant eye tearing and fingernail infections are really getting to me. My CT scans have shown "slight improvement," but I'm not sure if that's worth the side effects. I'm planning on discussing a change in treatment with my oncologist at my next appointment.
1Patient Review
6/18/2014 I had my 1st TCH on 6/11/14. Within 12 hours, I was in excruciating pain from lower back to knees. The pain lasted 3 days. On day 6, my infusion arm started turning red and itching. Day 7, I have a rash on my infusion hand/wrist that is red and itchy. My mouth and tongue are swollen and I have sores on the sides of my tongue. I have 5 more rounds to go. I am meeting with my Oncologist before my next treatment on 7/1/14. Praying he will change my treatment plan!
Patient Q&A Section about taxotere
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Taxotere?
"-Side effects such as pain or swelling at the injection site, nausea, vomiting, diarrhea, excessive tearing, fatigue, dizziness, drowsiness, feeling drunk, constipation, and loss of appetite may occur.
-Temporary hair loss and nail changes may also occur.
-This medication can decrease your body's ability to fight an infection."
Answered by AI
What is the most common side effect of docetaxel?
"Two common long-term side effects of docetaxel chemotherapy are sensory and motor [peripheral neuropathy](https://www.withpower.com/clinical-trials/peripheral-neuropathy), which are less severe than with paclitaxel. Grade 3 and 4 neuropathy is only observed in less than 10% of patients receiving docetaxel therapy."
Answered by AI
How long can you take Taxotere?
"Health care providers give Taxotere to their patients through an IV. The IV takes one hour to administer the drug, and this happens every three weeks. Depending on the type of cancer, the patient may have to go through several cycles of this treatment."
Answered by AI
Is Taxotere a strong chemo drug?
"Because Taxotere is a strong chemotherapy drug, its side effects tend to be more extreme than drugs that treat other, less serious issues. To deal with these side effects, doctors may lower the dose or prescribe drugs that reduce the risk of allergic reactions."
Answered by AI